CD8A and melanoma: Among these, DMXAA, initially identified as a potent vascular‐disrupting agent, was later recognized as a strong STING agonist in mice.[22] It exhibited robust antitumor effects in melanoma, breast cancer, and fibrosarcoma models, with tumor suppression highly dependent on the STING pathway and CD8+ T cells.[23] This promising STING‐driven antitumor activity led to its advancement into clinical trials.